MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines

被引:222
作者
Bemis, Lynne T. [1 ]
Chen, Robert [1 ]
Amato, Carol M. [1 ]
Classen, Elizabeth H. [1 ]
Robinson, Steven E. [1 ]
Coffey, David G. [1 ]
Erickson, Paul F. [1 ]
Shellman, Yiqun G. [2 ]
Robinson, William A. [1 ]
机构
[1] Univ Colorado, Denver Sch Med, Div Med Oncol, Aurora, CO 80045 USA
[2] Univ Colorado, Denver Sch Med, Dept Dermatol, Aurora, CO USA
关键词
D O I
10.1158/0008-5472.CAN-07-2912
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Micropthalmia-associated transcription factor (MITF) is the master regulator of melanocyte development, survival, and function. Frequent alteration in the expression of MITF is detected in melanoma, but the mechanism(s) underlying the alteration in expression have not been completely determined. In these studies, we have identified microRNA-137 (miR-137) as a regulator of MITF expression. The genomic locus of miR-137 at chromosome 1p22 places it in a region of the human genome previously determined to harbor an allele for melanoma susceptibility. Here, we show that expression of mature miR-137 in melanoma cell lines down-regulates MITF expression. Further, we have identified a 15-bp variable nucleotide tandem repeat located just 5' to the pre-miR-137 sequence, which alters the processing and function of miR-137 in melanoma cell lines.
引用
收藏
页码:1362 / 1368
页数:7
相关论文
共 29 条
[1]   Distinct pigmentary and melanocortin 1 receptor-dependent components of cutaneous defense against ultraviolet radiation [J].
April, Craig S. ;
Barsh, Gregory S. .
PLOS GENETICS, 2007, 3 (01) :0030-0043
[2]   Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance [J].
Calin, GA ;
Croce, CM .
SEMINARS IN ONCOLOGY, 2006, 33 (02) :167-173
[3]   A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia [J].
Calin, GA ;
Ferracin, M ;
Cimmino, A ;
Di Leva, G ;
Shimizu, M ;
Wojcik, SE ;
Iorio, MV ;
Visone, R ;
Sever, NI ;
Fabbri, M ;
Iuliano, R ;
Palumbo, T ;
Pichiorri, F ;
Roldo, C ;
Garzon, R ;
Sevignani, C ;
Rassenti, L ;
Alder, H ;
Volinia, S ;
Liu, CG ;
Kipps, TJ ;
Negrini, M ;
Croce, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (17) :1793-1801
[4]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[5]   The evolution of gene regulation by transcription factors and microRNAs [J].
Chen, Kevin ;
Rajewsky, Nikolaus .
NATURE REVIEWS GENETICS, 2007, 8 (02) :93-103
[6]   Central role of p53 in the suntan response and pathologic hyperpigmentation [J].
Cui, Rutao ;
Widlund, Hans R. ;
Feige, Erez ;
Lin, Jennifer Y. ;
Wilensky, Dara L. ;
Igras, Viven E. ;
D'Orazio, John ;
Fung, Claire Y. ;
Schanbacher, Carl F. ;
Granter, Scott R. ;
Fisher, David E. .
CELL, 2007, 128 (05) :853-864
[7]   Sequence variations of microRNAs in human cancer: Alterations in predicted secondary structure do not affect processing [J].
Diederichs, Sven ;
Haber, Daniel A. .
CANCER RESEARCH, 2006, 66 (12) :6097-6104
[8]   Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma [J].
Garraway, LA ;
Widlund, HR ;
Rubin, MA ;
Getz, G ;
Berger, AJ ;
Ramaswamy, S ;
Beroukhim, R ;
Milner, DA ;
Granter, SR ;
Du, JY ;
Lee, C ;
Wagner, SN ;
Li, C ;
Golub, TR ;
Rimm, DL ;
Meyerson, ML ;
Fisher, DE ;
Sellers, WR .
NATURE, 2005, 436 (7047) :117-122
[9]   MicroRNA expression and function in cancer [J].
Garzon, Ramiro ;
Fabbri, Muller ;
Cimmino, Amelia ;
Calin, George A. ;
Croce, Carlo M. .
TRENDS IN MOLECULAR MEDICINE, 2006, 12 (12) :580-587
[10]   Localization of a novel melanoma susceptibility locus to 1p22 [J].
Gillanders, E ;
Juo, SHH ;
Holland, EA ;
Jones, M ;
Nancarrow, D ;
Freas-Lutz, D ;
Sood, R ;
Park, N ;
Faruque, M ;
Markey, C ;
Kefford, RF ;
Palmer, J ;
Bergman, W ;
Bishop, DT ;
Tucker, MA ;
Bressac-de Paillerets, B ;
Hansson, J ;
Stark, M ;
Gruis, N ;
Bishop, JN ;
Goldstein, AM ;
Bailey-Wilson, JE ;
Mann, GJ ;
Hayward, N ;
Trent, J .
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (02) :301-313